![Versanis Announces Initiation of the BELIEVE Global Phase 2b Study of Bimagrumab as a Novel Treatment for Obesity Versanis Announces Initiation of the BELIEVE Global Phase 2b Study of Bimagrumab as a Novel Treatment for Obesity](https://mma.prnewswire.com/media/1862610/Versanis_Bio_Logo.jpg?p=twitter)
Versanis Announces Initiation of the BELIEVE Global Phase 2b Study of Bimagrumab as a Novel Treatment for Obesity
Versanis Bio on Twitter: "Welcome to the Versanis Board of Directors, John Maraganore @JMaraganore! John brings decades of proven strategic and operational leadership experience in biotechnology to help Versanis realize the full
![Versanis' bimagrumab, first-in-class obesity therapy, enters Phase IIb of development - Pharmaceutical Technology Versanis' bimagrumab, first-in-class obesity therapy, enters Phase IIb of development - Pharmaceutical Technology](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2023/01/featured-image-1.jpg)
Versanis' bimagrumab, first-in-class obesity therapy, enters Phase IIb of development - Pharmaceutical Technology
![Versanis Bio Announces Leadership and Board Appointments as Company Prepares to Initiate Phase 2b Study with Novel Approach to Obesity Versanis Bio Announces Leadership and Board Appointments as Company Prepares to Initiate Phase 2b Study with Novel Approach to Obesity](https://mma.prnewswire.com/media/1862610/Versanis_Bio_Logo.jpg?p=facebook)